Assistant Professor of Pathology and Neuropathology, Stanford University
Dr. Inma Cobos is a physician-scientist and neuropathologist with expertise in neurodegeneration and developmental neuroscience. Dr. Cobos received her medical and doctoral degrees from the University of Murcia in Spain, where she trained with Dr. Luis Puelles and Dr. Salvador Martinez. She then completed post-doctoral training in developmental neurobiology at the University of California, San Francisco with Dr. John Rubenstein. She pursued a clinical residency and fellowship in anatomic pathology and neuropathology at Massachusetts General Hospital, Harvard Medical School, where she gained extensive experience and knowledge in the diagnosis and classification of neurodegenerative diseases. Before joining Stanford in 2019, she was an Assistant Professor in the Department of Pathology and Neuropathology at the UCLA David Geffen School of Medicine.
As a neuropathologist at Stanford’s Department of Pathology, she has clinical and educational responsibilities, including diagnostic surgical neuropathology of in-house and consult cases, intraoperative consultations, and brain autopsies. As the leader of the Stanford Alzheimer’s Disease Research Center (ADRC) Neuropathology Core, Dr. Cobos aims to bridge the research and clinical domains in neurodegeneration by building, maintaining, and expanding a high-quality brain tissue resource. She also oversees, diagnoses, and organizes didactic sessions surrounding dementia cases at the Department of Pathology and the Stanford ADRC.
Her research program combines her background in diagnostic neuropathology, knowledge of developmental neuroscience, and state-of-the-art cellular and molecular technologies to advance the understanding of Alzheimer’s disease and related dementias. Her lab uses single-cell approaches to gain insight into the cellular and molecular mechanisms underlying selective cell vulnerability in human brains with Alzheimer’s disease and mouse models of dementia. Her work is supported by the NIH National Institute on Aging, the Alzheimer’s Association, BrightFocus, and the Chan Zuckerberg Initiative (CZI) Neurodegeneration Challenge Network.
